Lilly Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LILLY, and what generic alternatives to LILLY drugs are available?
LILLY has one hundred and five approved drugs.
There is one US patent protecting LILLY drugs.
There are thirty patent family members on LILLY drugs in twenty-five countries and eighty-six supplementary protection certificates in thirteen countries.
Drugs and US Patents for Lilly
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | DELTALIN | ergocalciferol | CAPSULE;ORAL | 080884-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Lilly | SYMBYAX | fluoxetine hydrochloride; olanzapine | CAPSULE;ORAL | 021520-005 | Dec 24, 2003 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Lilly | DIETHYLSTILBESTROL | diethylstilbestrol | TABLET;ORAL | 004041-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Lilly | PAGITANE | cycrimine hydrochloride | TABLET;ORAL | 008951-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Lilly
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | 5,641,790 | ⤷ Try a Trial |
Lilly | DECABID | indecainide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019693-001 | Dec 29, 1989 | 4,389,393 | ⤷ Try a Trial |
Lilly | ALIMTA | pemetrexed disodium | POWDER;INTRAVENOUS | 021462-002 | Sep 7, 2007 | 5,217,974*PED | ⤷ Try a Trial |
Lilly | CIALIS | tadalafil | TABLET;ORAL | 021368-003 | Nov 21, 2003 | 6,821,975*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LILLY drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | For Injection | 750 mg/vial | ➤ Subscribe | 2016-10-06 |
➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2008-10-14 |
➤ Subscribe | Delayed-release Capsules | 20 mg, 30 mg and 60 mg | ➤ Subscribe | 2008-08-04 |
➤ Subscribe | Capsules | 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg | ➤ Subscribe | 2007-05-29 |
➤ Subscribe | Capsules | 3 mg/25 mg | ➤ Subscribe | 2008-05-08 |
➤ Subscribe | For Injection | 1g/vial | ➤ Subscribe | 2005-11-14 |
➤ Subscribe | For Injection | 100 mg/vial | ➤ Subscribe | 2008-07-01 |
➤ Subscribe | For Injection | 1000 mg/vial | ➤ Subscribe | 2012-06-27 |
➤ Subscribe | Injection | 250 mcg/mL, 2.4 mL prefilled Pen | ➤ Subscribe | 2015-07-27 |
➤ Subscribe | Tablets | 5 mg, 10 mg and 20 mg | ➤ Subscribe | 2007-11-21 |
➤ Subscribe | Delayed-release Capsules | 40 mg | ➤ Subscribe | 2012-05-10 |
➤ Subscribe | Capsules | 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg | ➤ Subscribe | 2005-01-10 |
➤ Subscribe | For Injection | 200 mg/vial | ➤ Subscribe | 2005-11-01 |
➤ Subscribe | For Injection | 2 g/vial | ➤ Subscribe | 2007-08-24 |
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-02-04 |
International Patents for Lilly Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Denmark | 1732629 | ⤷ Try a Trial |
Norway | 20064955 | ⤷ Try a Trial |
Hungary | E045180 | ⤷ Try a Trial |
Canada | 2557897 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lilly Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1280520 | C300722 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720 |
1539166 | 92323 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624 |
2101777 | 93081 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125 |
2365988 | 122018000012 | Germany | ⤷ Try a Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM UND SALZE DAVON IN ALLEN VOM GRUNDPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/17/1179 20170719 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.